Home›Trial›NCT06911320
NCT06911320Phase 1RECRUITING

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Study Summary

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Conditions
Healthy Volunteer StudyHepatic ImpairmentRenal Impairment
Interventions / Drugs
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
View on ClinicalTrials.gov ↗
Sponsor
AVIR
Atea Pharmaceuticals
Infectious Disease
D42/100
Study Details
Enrollment28 participants
Primary Completion—
Lead SponsorAtea Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:55:17.105140+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 28 participants
Sponsor Catalyst Profile

Atea Pharmaceuticals (AVIR) is the sponsoring company for this trial. BiotechSign currently grades this company D (42/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

AVIR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.